Lydall, Inc. News Headlines

LDL 
$22.48
*  
0.41
 negative 
1.79%
Get LDL Alerts
*Delayed - data as of Apr. 23, 2014 
Exchange: NYSE
Industry: Capital Goods
Community Rating:
View:    LDL After Hours
 
 
Symbol List Views
FlashQuotes InfoQuotes
Stock Details
Summary Quote Real-Time Quote After Hours Quote Pre-market Quote Historical Quote Option Chain
CHARTS
Basic Chart Interactive Chart
COMPANY NEWS
Company Headlines Press Releases Market Stream
STOCK ANALYSIS
Analyst Research Guru Analysis Stock Report Competitors Stock Consultant Stock Comparison
FUNDAMENTALS
Call Transcripts Annual Report Income Statement Revenue/EPS SEC Filings Short Interest Dividend History
HOLDINGS
Ownership Summary Institutional Holdings Insiders
(SEC Form 4)
 Save stocks for next time
Viewing
Filtered By
Ordered By

Canadian Nod for Aegerion's Juxtapid - Analyst Blog
2/11/2014 5:45:01 PM - Zacks.com

Pipeline Progress at Alnylam - Analyst Blog
10/14/2013 3:46:10 PM - Zacks.com

Aegerion's Lojuxta Gets EU Approval - Analyst Blog
8/5/2013 5:20:01 PM - Zacks.com

3 IPOs That Could Be Tomorrow's Superstars
7/26/2013 3:30:00 PM - StreetAuthority

Lydall Is Undervalued With Improving Fundamentals
7/2/2013 4:39:00 AM - Seeking Alpha

CHMP Positive on Aegerion's Lojuxta - Analyst Blog
6/3/2013 5:25:58 PM - Zacks.com

FDA Accepts Merck BLA - Analyst Blog
5/15/2013 12:30:44 PM - Zacks.com

Merck's Liptruzet Approved in the US - Analyst Blog
5/7/2013 12:22:40 PM - Zacks.com

Pivotal Progresses with Vascazen - Analyst Blog
4/16/2013 7:06:56 PM - Zacks.com

Eli Lilly's Livalo: A Big Win For Patients And Investors
3/28/2013 4:13:00 PM - Seeking Alpha

Mylan Launches Generic Lipitor - Analyst Blog
5/31/2012 5:31:07 PM - Zacks.com